Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

Blood sugar and insulin levels also depend on the vagus nerve. As blood sugar levels rise, the vagus nerve stimulates the ...

The US Food and Drug Administration (FDA) has issued warning letters to four companies selling unapproved glucagon-like ...

Researchers have achieved impressive results in animal studies with a new weight-loss drug that has no GLP-1-style side ...

Researchers have discovered that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor ...

Shares of Viking Therapeutics (VKTX) are down $2.70, or 6%, to $44.00 in pre-market trading following Merck (MRK) and Chinese biopharmaceutical ...

The US data suggest that the South has seen the greatest shifts, and the highest rate of GLP-1 prescribing per capita.

Nutraceuticals offer potential health benefits, from migraine relief to cognitive support, but safety and regulatory issues ...

Newer glucose-lowering drugs reduce the risk for late-onset seizures and epilepsy by 24%, with GLP-1 RAs cutting the risk by ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

The most-read obesity articles of 2024 mostly focused on insurance coverage of weight loss medications and costs.

Merck (MRK) secured exclusive rights to develop and sell an oral weight loss drug under a license deal with Hansoh Pharma that could fetch the Chinese biopharmaceutical company up to $2 billion. Merck ...